 Arrowhead Pharmaceuticals NASDAQ:ARWR was upgraded by stock analysts at BidaskClub from a hold rating to a buy rating in a research report issued to clients and investors on Thursday, BidAskClub reports. A number of other research firms also recently issued reports on ARWR. Royal Bank of Canada began coverage on shares of Arrowhead Pharmaceuticals in ... 